A multicentre study on 89SrCl2 therapy in patients with painful bone metastases
刘兴党,张光明,蒯大禹,林祥通,陈绍亮,李蓓蕾,李林法,朱阳军,刘增礼,唐军,莫逸,易济民,石峰,贺佳,马修强
DOI: https://doi.org/10.3760/cma.j.issn.2095-2848.2007.04.017
2007-01-01
Abstract:Objective The aim of the study was to systematically compare the efficacy,toxicity of ~(89)SrCl_2 produced domestically(Chengdu Gaotong Isotope Cooperation)with Metastron(Amersham)in pallia- tion of painful skeletal metastases.Methods A multicenter clinical study was conducted during August 2004 to March 2005.Five Nuclear Medicine Departments participated.Ninety-four of 95 patients were trea- ted with a single intravenous dose(148 MBq)of ~(89)SrCl_2,30 received Metastron(group A)and 64 domestic product,the results could be evaluated.Patients were followed up for a period of 3 months.The results as pain relief and consumption of analgesic drugs,were expressed at four levels:1,no response;2,mild re- sponse;3,good response;4,excellent response.Results There was no difference in general information, physical strength,grades and positions of ache,compliance,security and use of drug between groups A and B.In per protocol set(PPS)group,response rate in group A was 66.67%,in group B 71.43%,with no significant difference between two groups.In full analysis set(FAS),response in group A and B was 66.67% and 70.31%,respectively.Haematological toxicity mainly affected PLT and WBC,with no signif- icant difference between two groups.Conclusion Good pain palliation in patients with bone metastases could be achieved with ~(89)SrCl_2,whether produced domestically or imported.